摘要:
The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
摘要翻译:本发明涉及包含SEQ ID NO:1,2和3的所有重链可变CDR区和/或SEQ ID NO:4,5和6的所有轻链可变CDR区的抗TNF抗体, 特异于至少一种人肿瘤坏死因子α(TNF)蛋白或其片段,以及编码这种抗TNF抗体的核酸,互补核酸,载体,宿主细胞,生产方法和治疗方法。
摘要:
The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
摘要翻译:本发明涉及包含SEQ ID NO:1,2和3的所有重链可变CDR区和/或SEQ ID NO:4,5和6的所有轻链可变CDR区的抗TNF抗体, 特异于至少一种人肿瘤坏死因子α(TNF)蛋白或其片段,以及编码这种抗TNF抗体的核酸,互补核酸,载体,宿主细胞,生产方法和治疗方法。
摘要:
The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
摘要:
Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriatic arthritis.
摘要:
The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.
摘要翻译:本发明涉及通过施用包含SEQ ID NO:7的重链可变区和SEQ ID NO:8的轻链可变区的抗TNF抗体来抑制具有类风湿性关节炎,银屑病关节炎或强直性脊柱炎的患者中的TNF, 特异于至少一种人肿瘤坏死因子α(TNF)蛋白或其片段。
摘要:
Described and claimed herein are combinatorial synthetic Fab libraries displayed on a phage pIX protein. The libraries were built on scaffolds representing the most frequently used genes in human antibodies, which were diversified to mirror the variability of natural antibodies. After selection using a diverse panel of proteins, numerous specific and high-affinity Fabs were isolated. By a process called in-line maturation the affinity of some antibodies was improved up to one hundred-fold yielding low pM binders suitable for in vivo use. This work thus demonstrates the feasibility of displaying complex Fab libraries as pIX-fusion proteins for antibody discovery and lays the foundations for studies on the structure-function relationship of antibodies.
摘要:
Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
摘要:
Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
摘要:
The present invention relates to at least one novel human EPO mimetic CH1 deleted mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic CH1 deleted mimetibody or specified portion or variant, CH1 deleted mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
摘要:
The present invention relates to at least one human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.